Health Prob Civil.
1. Madnani RS. Alzheimer’s disease: a mini-review for the clinician. Front Neurol. 2023; 14. https://doi.org/10.3389/fneur.2023.1178588
2.
Bomasang-Layno E, Bronsther R. Diagnosis and treatment of Alzheimer’s disease: an update. Dela J Public Health. 2021; 7. https://doi.org/10.32481/djph.2021.09.009
3.
Barcikowska M, Barczak A, Gabryelewicz T, Gałązka-Sobotka M,
4.
Gorzkowska A, Klimkowicz-Mrowiec A, et al. [National Health Fund on health. Alzheimer's disease and related diseases] [Internet]. Warsaw: National Health Fund; 2022 [access 2024 Feb 5]. Available from: https://ezdrowie.gov.pl/pobierz/raport_alzheimer (in Polish).
5.
Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, et al. Preclinical Alzheimer’s disease: definition, natural history, and diagnostic criteria. Alzheimer’s and Dementia, 2016; 12: 292-323. https://doi.org/10.1016/j.jalz.2016.02.002
6.
Barczak, A. The Early Diagnosis of Alzheimer’s Disease. Pediatria i Medycyna Rodzinna 2018, 14, 157–166. https://doi.org/10.15557/PiMR.2018.0016
7.
Kloske CM, Barnum CJ, Batista AF, Bradshaw EM, Brickman AM, Bu G, et al. APOE and immunity: research highlights. Alzheimer’s and Dementia. 2023; 19: 2677-2696. https://doi.org/10.1002/alz.13020
8.
Weisgraber KH, Mahley RW, Kowal RC, Herz J, Goldstein JL, Brown MS. Apolipoprotein C-I modulates the interaction of apolipoprotein e with β-migrating very low density lipoproteins (β-VLDL) and inhibits binding of β-VLDL to low density lipoprotein receptor-related protein. Journal of Biological Chemistry. 1990; 265: 22453-22459. https://doi.org/10.1016/S0021-9258(18)45726-2
9.
Meyer MR, Tschanz JT, Norton MC, Welsh-Bohmer KA, Steffens DC, Wyse BW, et al. APOE genotype predicts when – not whether – one is predisposed to develop Alzheimer disease. Nat Genet. 1998; 19: 321-322. https://doi.org/10.1038/1206
10.
Utermann G, Langenbeck U, Beisiegel U, Weber W. Genetics of the Apolipoprotein E system in man. Am J Hum Genet. 1980; 32(3): 339-347.
11.
Riddell DR, Zhou H, Atchison K, Warwick HK, Atkinson PJ, Jefferson J, et al. Impact of Apolipoprotein E (ApoE) polymorphism on brain ApoE levels. Journal of Neuroscience. 2008, 28; 11445-11453. https://doi.org/10.1523/JNEUROSCI.1972-08.2008
12.
Yamazaki Y, Zhao N, Caulfield TR, Liu CC, Bu G. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol. 2019; 15: 501-518. https://doi.org/10.1038/s41582-019-0228-7
13.
Liehn EA, Ponomariov V, Diaconu R, Streata I, Ioana M, Crespo-Avilan GE, et al. Apolipoprotein E in cardiovascular diseases: novel aspects of an old-fashioned enigma. Arch Med Res. 2018; 49: 522-529. https://doi.org/10.1016/j.arcmed.2018.08.008
14.
Kara E, Marks JD, Roe AD, Commins C, Fan Z, Calvo-Rodriguez M, et al. A flow cytometry–based in vitro assay reveals that formation of Apolipoprotein E (ApoE)–amyloid beta complexes depends on ApoE isoform and cell type. Journal of Biological Chemistry. 2018; 293: 13247-13256. https://doi.org/10.1074/jbc.RA117.001388
15.
Liu S, Liu J, Weng R, Gu X, Zhong Z. Apolipoprotein E gene polymorphism and the risk of cardiovascular disease and type 2 diabetes. BMC Cardiovasc Disord. 2019; 19. https://doi.org/10.1186/s12872-019-1194-0
16.
Mahley RW. Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders. J Mol Med. 2016; 94: 739-746. https://doi.org/10.1007/s00109-016-1427-y
17.
Chen F, Ke Q, Wei W, Cui L, Wang Y. Apolipoprotein E and viral infection: risks and mechanisms. Mol Ther Nucleic Acids. 2023; 33: 529-542. https://doi.org/10.1016/j.omtn.2023.07.031
18.
Hauser PS, Ryan RO. Impact of Apolipoprotein E on Alzheimer’s disease. Curr Alzheimer Res. 2013; 10(8): 809-817. https://doi.org/10.2174/15672050113109990156
19.
Yang LG, March ZM, Stephenson RA, Narayan PS. Apolipoprotein E in lipid metabolism and neurodegenerative disease. Trends in Endocrinology and Metabolism. 2023; 34: 430-445. https://doi.org/10.1016/j.tem.2023.05.002
20.
Rall SC, Mahley RW. The role of Apolipoprotein E genetic variants in lipoprotein disorders. J Intern Med. 1992; 231: 653-659. https://doi.org/10.1111/j.1365-2796.1992.tb01254.x
21.
Evans D, Bode A, Lippe der von G, Beli FU, Mann WA. Cerebrovascular atherosclerosis in type iii hyperlipidemia is modulated by variation in the Apolipoprotein A5 gene. Eur J Med Res. 2011; 16: 79-84. https://doi.org/10.1186/2047-783X-16-2-79
22.
Marais AD, Solomon GAE, Blom DJ. Dysbetalipoproteinaemia: A mixed hyperlipidaemia of remnant lipoproteins due to mutations in Apolipoprotein E. Crit Rev Clin Lab Sci. 2014; 51: 46-62. https://doi.org/10.3109/10408363.2013.870526
23.
Kucharska E. [Arteriosclerosis – selected aspects]. Przegl. Lek. 2014; 71: 400-402 (in Polish).
24.
Caetano AP. Anemia Investigation reveals a primary sea-blue histiocyte syndrome. International Journal of Pathology and Clinical Research. 2016; 2. https://doi.org/10.23937/2469-5807/1510019
25.
Nguyen TT, Kruckeberg KE, O’Brien JF, Ji ZS, Karnes PS, Crotty TB, et al. Familial splenomegaly: macrophage hypercatabolism of lipoproteins associated with Apolipoprotein E mutation [Apolipoprotein E (149 Leu)]. J Clin Endocrinol Metab. 2000; 85(11): 4354-4358. https://doi.org/10.1210/jcem.85.11.6981
26.
Mosca S, Araújo G, Costa V, Correia J, Bandeira A, Martins E, et al. Dyslipidemia diagnosis and treatment: risk stratification in children and adolescents. J Nutr Metab. 2022; 2022: 1-10. https://doi.org/10.1155/2022/4782344
27.
Jones NS, Rebeck GW. The synergistic effects of APOE genotype and obesity on Alzheimer’s disease risk. Int J Mol Sci. 2019; 20(1): 63. https://doi.org/10.3390/ijms20010063
28.
Kypreos KE, Karagiannides I, Fotiadou EH, Karavia EA, Brinkmeier MS, Giakoumi SM, et al. Mechanisms of obesity and related pathologies: role of Apolipoprotein E in the development of obesity. FEBS J. 2009; 276: 5720-5728. https://doi.org/10.1111/j.1742-4658.2009.07301.x
29.
Wei X, Yan-Lin M, Chi C, Sheng-Miao F, Jin-Ju Z, Shui-Ping Y, et al. Apolipoprotein E gene expression in peripheral blood monocyte in children with obesity. Zhonghua Er Ke Za Zhi. 2003; 41(10): 755-760.
30.
Silva MVF, Loures CD, Alves LC, De Souza LC, Borges KB, Carvalho MD. Alzheimer’s disease: risk factors and potentially protective measures. J Biomed Sci. 2019; 26. https://doi.org/10.1186/s12929-019-0524-y
31.
Hausz-Piskorz B, .; Buczkowski, K. “Diagnostyka i leczenie choroby Alzheimera w warunkach praktyki lekarza rodzinnego”, Forum Medycyny Rodzinnej 2013, tom 7, nr 4, 198–207
32.
Michaelson DM. APOE Ε4: the most prevalent yet understudied risk factor for Alzheimer’s disease. Alzheimer’s and Dementia. 2014; 10: 861-868. https://doi.org/10.1016/j.jalz.2014.06.015
33.
Chávez-Fumagalli MA, Shrivastava P, Aguilar-Pineda JA, Nieto-Montesinos R, Del-Carpio GD, Peralta-Mestas A, et al. Diagnosis of Alzheimer’s disease in developed and developing countries: systematic review and meta-analysis of diagnostic test accuracy. J Alzheimers Dis Rep. 2021; 5: 15-30. https://doi.org/10.3233/ADR-200263
34.
Porsteinsson AP, Isaacson RS, Knox S, Sabbagh MN, Rubino I. Diagnosis of early Alzheimer’s disease: clinical practice in 2021. Journal of Prevention of Alzheimer’s Disease. 2021; 8: 371-386. https://doi.org/10.14283/jpad.2021.23
Copyright: © 2024 Pope John Paul II State School of Higher Education in Biała Podlaska. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
